[go: up one dir, main page]

CA2351587A1 - Vecteurs viraux a expression tardive de transgenes - Google Patents

Vecteurs viraux a expression tardive de transgenes Download PDF

Info

Publication number
CA2351587A1
CA2351587A1 CA002351587A CA2351587A CA2351587A1 CA 2351587 A1 CA2351587 A1 CA 2351587A1 CA 002351587 A CA002351587 A CA 002351587A CA 2351587 A CA2351587 A CA 2351587A CA 2351587 A1 CA2351587 A1 CA 2351587A1
Authority
CA
Canada
Prior art keywords
virus
cell
gene
cells
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002351587A
Other languages
English (en)
Inventor
Kenneth N. Wills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2351587A1 publication Critical patent/CA2351587A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des virus recombinés contenant un transgène thérapeutique lié fonctionnellement à un élément régulateur tardif. Les vecteurs de la présente invention sont capables d'une réplication et d'une lyse de cellules néoplasiques. Les vecteurs peuvent comprendre facultativement des modifications apportées au génome de manière à conférer des fonctions de réplication ou de ciblage thérapeutique conditionnelles supplémentaires. La présente invention concerne également des formulations pharmaceutiques de ces vecteurs. En outre, la présente invention concerne des méthodes d'utilisation de ces vecteurs et des méthodes de préparation des vecteurs.
CA002351587A 1998-11-18 1999-11-17 Vecteurs viraux a expression tardive de transgenes Abandoned CA2351587A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19536798A 1998-11-18 1998-11-18
US09/195,367 1998-11-18
PCT/US1999/026004 WO2000029599A1 (fr) 1998-11-18 1999-11-17 Vecteurs viraux a expression tardive de transgenes

Publications (1)

Publication Number Publication Date
CA2351587A1 true CA2351587A1 (fr) 2000-05-25

Family

ID=22721149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351587A Abandoned CA2351587A1 (fr) 1998-11-18 1999-11-17 Vecteurs viraux a expression tardive de transgenes

Country Status (6)

Country Link
EP (1) EP1131458A1 (fr)
JP (1) JP2002530085A (fr)
AR (1) AR021318A1 (fr)
AU (1) AU2344100A (fr)
CA (1) CA2351587A1 (fr)
WO (1) WO2000029599A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
AU767904B2 (en) * 1999-05-12 2003-11-27 Uab Research Foundation, The Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
GB0014820D0 (en) * 2000-06-16 2000-08-09 Medical Res Council Methods and materials relating to plasmid vectors
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
WO2002068627A2 (fr) 2001-02-23 2002-09-06 Novartis Ag Nouvelles constructions de vecteurs
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2806883B1 (fr) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarqueurs et polythérapies utilisant un virus oncolytique et l'immunomodulation
SG10201913795TA (en) 2012-02-02 2020-03-30 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
EP3341012B1 (fr) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720277B1 (fr) * 1994-05-31 1996-07-12 Rhone Poulenc Rorer Sa Méthode de traitement des cancers par régulation de la protéine P53.
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus

Also Published As

Publication number Publication date
EP1131458A1 (fr) 2001-09-12
AU2344100A (en) 2000-06-05
WO2000029599A1 (fr) 2000-05-25
AR021318A1 (es) 2002-07-17
JP2002530085A (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
JP4334174B2 (ja) 腫瘍崩壊性アデノウイルス
US8133481B2 (en) Selectively replicating viral vectors
JP2009254385A (ja) 選択的に複製するウイルスベクター
US6649158B1 (en) Methods and compositions to induce antitumor response
CA2351587A1 (fr) Vecteurs viraux a expression tardive de transgenes
US7078030B2 (en) Oncolytic adenovirus
WO2000022124A2 (fr) Procedes et compositions permettant d'induire une reponse antitumorale
JP2002527455A (ja) 組換え欠失アデノウイルスベクター
WO2000029573A2 (fr) Vecteurs adenoviraux
MXPA01004989A (en) Viral vectors with late transgene expression
MXPA01003840A (en) Selectively replicating viral vectors

Legal Events

Date Code Title Description
FZDE Dead